Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions
Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension
Bosentan